E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Metastatic triple negative Breast Cancer |
|
E.1.1.1 | Medical condition in easily understood language |
Metastatic triple negative Breast Cancer |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10027475 |
E.1.2 | Term | Metastatic breast cancer |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Progression Free Survival (PFS) defined as the number of days between the date of randomization and the date of clinical disease progression (PD) according RECIST criteria version 1.1, as assessed by Independent Radiology Review, or death for any cause, whichever occurs first. |
|
E.2.2 | Secondary objectives of the trial |
To determine the median PFS (mPFS)
To determine Overall Survival (OS).
To evaluate Objective Response Rates (ORR)
To assess the safety of the combination of paclitaxel and orally administered reparixin.
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
evaluation of CD24-CD44+CSC, ALDH+CSC. |
|
E.3 | Principal inclusion criteria |
1.Female aged > 18 years.
2.Patients with pathologically documented metastatic triple negative breast cancer (TNBC), eligible for treatment with paclitaxel. Paraffin-embedded tissue must be available from metastatic sites, if reasonably accessible, or from the primary tumor, to confirm the diagnosis of TNBC and for correlative studies (only on metastatic tissue). Fifteen slides can be obtained if the full block is not available to be sent or released.
TNBC will be defined as breast cancer with <1% ER+ and <1% PgR+ cells, and HER2 immunohistochemistry score of 0 or 1+ and/or in situ hybridization (ISH) with HER2 gene copy number <4 or a ratio of less than 2 between HER2 gene copy number and centromere of chromosome 17. Patients whose metastatic disease is TNBC are eligible even when their primary tumor expressed hormone receptors and/or HER2.
3.Patients must be newly diagnosed metastatic or have relapsed following a prior (neo)adjuvant chemotherapy regimen. If a taxane (i.e., paclitaxel or docetaxel) was administered as part of the (neo)adjuvant regimen, PD must have occurred > 12 months from the end of previous (neo)adjuvant treatment. For non-taxane (neo)adjuvant regimen, PD must have occurred > 6 months from the end of previous (neo)adjuvant treatment
4.Patients with at least one baseline measurable lesion according to RECIST criteria version 1.1.
5.Zubrod (Eastern Co-operative Oncology Group [ECOG]) Performance Status (PS) of 0 1.
6.Life expectancy of at least three months.
7.Patients must be able to swallow and retain oral medication (intact tablet).
8.Able to undergo all screening assessments outlined in the protocol.
9.Adequate organ function (defined by the following parameters):
a)Serum creatinine < 140 µmol/L (< 1.6 mg/dL) or creatinine clearance > 60 mL/min.
b)Serum hemoglobin ≥ 9 g/dL; absolute neutrophil count ≥ 1.5 x 109/L; platelets ≥ 100 x 109/L.
c)Serum bilirubin ≤ 1.5 x upper normal limit (UNL) except patients with Gilbert’s syndrome
d)Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ 2.5 x UNL but ≤ 5.0 x UNL in case of liver metastases; alkaline phosphatase (ALP) ≤ UNL but I) ≤ 2.5 x ULN in case of liver metastases and ii) ≤ 5x ULN in case of bone metastases; albumin > 2.5g/dl.
10.No history or evidence by CT scan or MRI, of brain metastases or leptomeningeal disease.
11.No known hepatitis B virus (not due to immunization), hepatitis C virus, human immunodeficiency virus I and II positive status.
12.Dated and signed IEC/IRB-approved informed consent.
13. No history or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Medical Monitor, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion |
|
E.4 | Principal exclusion criteria |
2.Prior therapy for metastatic TNBC (chemotherapy, hormone therapy or biological therapy), Patients may receive bisphosphonates and other therapies to treat bone metastases, however if used, bone lesions will not be considered as measurable disease.
3.Less than four weeks since last radiotherapy (excluding palliative radiotherapy).
4.Pregnancy or lactation or unwillingness to use adequate method of birth control.
5.Neurological or psychiatric disorders which may influence understanding of study and informed consent procedures.
6.Active or uncontrolled infection.
7.Malabsorption syndrome, disease significantly affecting gastrointestinal function.
8.G>1 pre-existing peripheral neuropathy
9.Any other invasive malignancy from which the patient has been disease-free for less than 5 years with the exception of curatively treated basal or squamous cell skin cancer
10.Hypersensitivity to:
a)paclitaxel
b)ibuprofen or to more than one non-steroidal anti-inflammatory drug.
c)more than one medication belonging to the class of sulfonamides, such as sulfamethazine, sulfamethoxazole, sulfasalazine, nimesulide or celecoxib; hypersensitivity to sulphanilamide antibiotics alone (e.g.sulfamethoxazole) does not qualify for exclusion.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Progression Free Survival (PFS) defined as the number of days between the date of randomization and the date of clinical disease progression (PD) according to RECIST criteria version 1.1, as assessed by Independent Radiology Review, or death for any cause, whichever occurs first. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
at disease progression or death whichever occurs before |
|
E.5.2 | Secondary end point(s) |
1)median PFS (mPFS)defined as the number of days between the date of randomization and the date of clinical disease progression (PD) according to RECIST criteria version 1.1, or death for any cause, whichever occurs first
2)overall Survival defined as the interval (days) between randomization and death from any cause.
3)objective response rates (ORR) defined as the percentage of the patients reaching complete remission (CR), partial remission (PR) or stable disease (SD) according to RECIST criteria version 1.1.
• CR rate
• PR rate
• SD rate
• PD rate
4) safety of the combination treatment
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1) at disease progression or death
2) death
3) every eight weeks until disease progresion or death wichever occurs first
4) throughout the study |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 42 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belgium |
Czech Republic |
France |
Italy |
Poland |
Spain |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 5 |